How Quickly Does Cosentyx Start Relieving AS Symptoms?
Cosentyx (secukinumab), an IL-17 inhibitor for ankylosing spondylitis (AS), shows initial relief in many patients within 1-2 weeks. ASAS20 response—meaning 20% improvement in AS symptoms like back pain and stiffness—occurs in about 60% of patients by week 2.[1][2]
What Do Clinical Trials Show for Onset Timeline?
In the MEASURE 1 and MEASURE 2 trials, subcutaneous Cosentyx at 150mg or 75mg doses led to:
- ASAS20 in 59-61% of patients by week 2 (vs. 28% placebo).
- ASAS40 (40% improvement) by week 4 in 44-48%.
- Median time to onset of substantial improvement: around 2 weeks for pain and function.[1][3]
Intravenous loading dose (as in PREVENT trial) speeds this slightly, with ASAS40 in 66% by week 2.[1]
When Do Patients Typically Feel Full Relief?
Peak benefits build over 12-16 weeks. By week 16:
- ASAS40 reaches 66-71%.
- BASDAI50 (50% drop in disease activity) in 58-64%.[1][2]
Some report less stiffness within days, but data confirms reliable onset by week 2 for most responders.
Why Does Onset Vary Between Patients?
Factors include baseline disease severity, prior treatments (e.g., slower if TNF inhibitor failures), and dosing. Non-responders by week 4 rarely improve later.[1] Adalimumab head-to-head trials show similar week 2 onset (61% ASAS20 for Cosentyx vs. 47%).[4]
What If Relief Doesn't Start by Week 2?
Guidelines suggest reassessing at 3 months; switch if no ASAS20/40. No rapid rebound on discontinuation, but symptoms return over weeks.[1][5]
[1]: Cosentyx Prescribing Information (Novartis)
[2]: Baeten D et al. Lancet. 2015;385(9979):1688-97
[3]: van der Heijde D et al. Ann Rheum Dis. 2017;76(7):1346-52
[4]: Baeten D et al. Ann Rheum Dis. 2018;77(12):1730-40
[5]: van der Heijde D et al. Rheumatology (Oxford). 2018;57(6):1069-81